Mesothelioma Lawyers

Author:

Standard treatment

options:

1. Symptomatic treatment to include drainage of effusions,

   chest tube

   pleurodesis, or thoracoscopic pleurodesis.

2. Palliative surgical resection

   in selected patients.

3. Palliative radiation therapy.
4. Single-agent chemotherapy. Partial responses have been reported with

   doxorubicin, epirubicin, mitomycin, cyclophosphamide, cisplatin, carboplatin,

   and ifosfamide.

5. Combination chemotherapy (under clinical evaluation). Information

   about ongoing clinical trials is available from the NCI

   Cancer.gov Website.

6. Multimodality clinical trials.
7. Intracavitary

   therapy. Intrapleural or intraperitoneal administration

   of

   chemotherapeutic agents (e.g., cisplatin, mitomycin,

   and cytarabine) has been

   reported to produce transient

   reduction in the size of tumor masses and

   temporary control of effusions in small clinical studies. Additional

   studies are needed to define the role of intra-cavitary therapy.

The safety and efficacy of pemetrexed, an antifolate, and

cisplatin in chemotherapy-n aive patients with malignant mesothelioma

who were not eligible for curative

surgery....[MORE]